Payment overview · 2025
General Payments
$1,145.29
42 reported records · 12 companies
Healthcare provider profile · identity verified
Matthew Bosarge, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · GULFPORT, MS · NPI 1336674803
Verified facts
What the public records show
CMS Open Payments records show Matthew Bosarge, D.O. received $1,145.29 in general payments during 2025 across 42 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $341.21 | 29.8% | 7 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $272.84 | 23.8% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $127.87 | 11.2% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $124.76 | 10.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $93.52 | 8.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.67 | 4.7% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $31.68 | 2.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.95 | 2.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.43 | 1.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.59 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.86 | 1.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.91 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,145.29 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $272.84 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $166.29 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $127.87 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $126.97 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $125.88 | 7 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $109.65 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $93.52 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $73.35 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $53.67 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $31.68 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 79 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
63 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
79 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
64 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 299 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 253 | 77 |
| Gabapentin | Gabapentin | 206 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 155 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 49 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 134 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 128 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 46 |
| Lisinopril | Lisinopril | 122 | 33 |
| Losartan Potassium | Losartan Potassium | 101 | 34 |
| Montelukast Sodium | Montelukast Sodium | 99 | 34 |
| Trazodone Hcl | Trazodone Hcl | 94 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 29 |
| Metformin Hcl | Metformin Hcl | 82 | 34 |
| Omeprazole | Omeprazole | 82 | 29 |
| Mounjaro | Tirzepatide | 79 | 18 |
| Jardiance | Empagliflozin | 72 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 16 |
| Carvedilol | Carvedilol | 71 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 25 |
| Tramadol Hcl | Tramadol Hcl | 67 | 17 |
| Trulicity | Dulaglutide | 64 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 19 |
| Furosemide | Furosemide | 59 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 19 |
| Potassium Chloride | Potassium Chloride | 49 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 23 |
| Mirtazapine | Mirtazapine | 47 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 14 |
| Sertraline Hcl | Sertraline Hcl | 43 | 12 |
| Alendronate Sodium | Alendronate Sodium | 39 | 15 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 39 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 39 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 17 |
| Meloxicam | Meloxicam | 38 | suppressed |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 11 |
| Nystatin | Nystatin | 31 | suppressed |
| Cefdinir | Cefdinir | 30 | 26 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 13 |
| Simvastatin | Simvastatin | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Dexamethasone | Dexamethasone | 25 | 22 |
| Fluconazole | Fluconazole | 25 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | 11 |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | 11 |
| Synjardy | Empagliflozin/Metformin Hcl | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 16 |
| Glipizide | Glipizide | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Famotidine | Famotidine | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 12 |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Valsartan | Valsartan | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Celecoxib | Celecoxib | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,145.29 · 42 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, FARXIGA, INCEPTIV, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, KRYSTEXXA, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, YUPELRI, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error